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ABSTRACT
Distant metastasis remains the major failure of nasopharyngeal carcinoma 
(NPC). In this study, the roles of chemokine C-C motif ligand 2 (CCL2), and its 
receptor chemokine C-C motif receptor type 2 (CCR2) on NPC metastasis were 
investigated. Serum CCL2 and CCL2/CCR2 expression level were remarkably increased 
in NPC patients compared to non-tumor patients by ELISA and IHC analyses. High 
expressions of CCL2/CCR2 were significantly associated with NPC metastasis and poor 
overall survival (OS). High expression of CCR2 is an independent adverse prognostic 
factor of OS and distant metastasis free survival (DMFS). Overexpressions of CCL2 
and CCR2 were detected in high-metastatic NPC cell lines. Upregulating CCL2 and 
CCR2 respectively in low-metastatic NPC cell lines could promote cell migration and 
invasion, and exogenous CCL2 enhanced the motility in CCR2-overexpressing cells. 
On the other hand, downregulating CCL2 and CCR2 respectively in high-metastatic 
NPC cell lines by shRNA could decrease cell migration and invasion. However, 
exogenous CCL2 could not rescue the weaken ability of motility of CCR2-silencing 
cells. In nude mouse model, distant metastasis was significantly facilitated in either 
CCL2-overexpressing or CCR2-overexpressing groups, which was more obvious in 
CCR2-overexpressing group. Also, distant metastasis was considerably inhibited in 
either CCL2-silencing or CCR2-silencing groups. Dual overexpression of CCL2/CCR2 
could activate extracellular signal-regulated kinase (ERK1/2) signaling pathway, 
which sequentially induced matrix metalloproteinase (MMP) 2 and 9 upregulations 
in the downstream. In conclusion, CCL2-CCR2 axis could promote NPC metastasis by 
activating ERK1/2-MMP2/9 pathway. This study helps to develop novel therapeutic 
targets for distant metastasis in NPC.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is one of the most 
common malignancies in Southeast Asia and southern 
China with incidences reported as 15–50 per 100,000 [1–3]. 
Non-keratinizing carcinoma, the major histologic form 
of NPC, dominates in these high-incidence areas, with 
a feature of high distant metastasis rate at the time of 
diagnosis [4] or after initial treatment [5]. It is believed 
that the pathogenesis of NPC metastasis is an intricate 
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progressive process involving the accumulation of multi-
genetic alterations [6, 7], and the detailed molecular 
mechanisms are sparsely understood.
In the human genome, chemokine C–C motif 
ligand 2 (CCL2) gene is one of cytokine genes located 
at 17q11.2-q12. CCL2 belongs to the superfamily 
of secreted proteins of chemokines involved in 
immunoregulatory and inflammatory processes. It is 
a monomeric polypeptide contains a signal peptide of 
23 amino acids and primarily secreted by monocytes, 
macrophages and dendritic cells [8]. CCL2 has been 
implicated in etiopathogeneses of several non-neoplastic 
diseases including diabetes mellitus, rheumatoid arthritis, 
and certain neuronal degeneration [9–11]. It was also 
reported as an important promoter in the development 
and progression of many types of tumors by stimulating 
cell proliferation and migration directly and/or indirectly 
[12]. Chemokine C-C motif receptor type 2 (CCR2) is 
one significant type of cell surface receptors that bind 
CCL2 [12]. CCR2 gene is located at 3p21.31 encoding 
two isoforms (A and B) of CCR2 transcript variants, and 
our previous work has demonstrated that only isoform 
B could be detected in NPC. Certain functions of CCR2 
have been revealed when it binds CCL2 forming CCL2/
CCR2 axis, involving formation of atherosclerotic plaques 
[13], insulin resistance in obesity [14], and inflammatory 
responses against tumors [15–17]. Recent studies focused 
on breast cancer, prostate cancer, pancreatic cancer, 
and colorectal cancer implicated CCL2/CCR2 axis 
participated extensively in pathogeneses of tumorigenesis 
and metastasis [15, 18–22]. But so far there is no research 
reported to uncover the underlying function of CCL2/
CCR in NPC. One of our previous studies in NPC had 
shed a light on the relationship between the serum CCL2 
(sCCL2) level of patients and their prognosis, suggesting 
that high sCCL2 level predicts bone invasion, post-
treatment distant metastasis and poor overall survival in 
NPC patients [23].
Amounts of studies focused on molecular 
mechanisms of tumor progression have defined that 
the matrix metalloproteinase (MMP) family is largely 
involved in the metastasis process, by associating 
with the breakdown of extracellular matrix and tissue 
remodeling [24, 25]. Upregulations of MMP2, MMP7, 
and MMP9 have been mostly reported as enhancements 
to the migratory and invasive ability of cancer cells 
[26–33]. 
In this present study, the expression status CCL2/
CCR2 and the clinical significance in NPCs were studied. 
Both overexpression and silencing of CCL2 and CCR2 
were conducted respectively in vitro and in vivo to 
characterize the biologic effects of CCL2/CCR2 axis 
in NPCs. The mechanism investigation demonstrated 
that CCL2-CCR2 axis promotes metastasis of NPC by 
activating ERK1/2-MMP2/9 pathway. 
RESULTS
CCL2 and CCR2 are frequently upregulated in 
NPC tissues and highly metastatic NPC cell lines, 
and CCL2 is remarkably increased in the sera of 
NPC patients
A cohort of tissue samples containing 50 cases of 
primary NPCs and 50 cases of non-tumors was studied by 
immunohistochemistry (IHC). Upregulation of CCL2 was 
detected in 48/50 (96%) in NPCs as shown in Figure 1A, 
compared with 0/50 in the nontumorous tissues. Similarly, 
upregulation of CCR2 was detected in 49/50 (98%) in 
NPCs, compared with 0/50 in the nontumorous tissues 
(Figure 1A).
Western blot analysis showed that both CCL2 and 
CCR2 were overexpressed in NPC cell lines compared 
with immortalized nasopharyngeal epithelial cell line 
NP69. The overexpressions of CCL2 and CCR2 were 
much more obvious in highly metastatic cell lines 
(S18 and 5-8F) compared with poorly metastatic cell lines 
(S26 and SUNE1), (Figure 1B). 
ELISA analyses of human sera from 50 cases 
with NPC and their non-tumor counterparts showed that 
the mean serum CCL2 concentration of NPC patients 
(342.3 ± 238.3 pg/ml, range 106.2 pg/ml-1448.6 pg/ml) 
was significantly higher than the mean serum CCL2 
concentration of non-tumor patients (20.0 ± 7.0 pg/ml, 
range 15.0 pg/ml-45.3 pg/ml), (P ＜ 0.05, Figure 1C).
Clinical significances of the high expression 
levels of CCL2 and CCR2 in NPC
To investigate the underlying clinical significance 
of CCL2/CCR2 axis, the associations of CCL2/CCR2 
expression levels with clinicopathological features in 
107 NPCs (informative IHC cases) were analyzed. The 
results found that high expression level of CCL2 was 
significantly associated with N stage (P = 0.005), and high 
expression level of CCR2 was significantly associated 
with distant metastasis (P = 0.032) and prognosis 
(P = 0.001, Table 1). Among them, 28.0% (n = 30) of 
107 patients displayed high expression of CCL2/CCR2 
axis (both positive of CCL2 and CCR2). Kaplan-Meier 
analysis indicated that higher CCL2 or CCR2 expression 
was significantly associated with poorer OS (log-rank test, 
P = 0.011 and P = 0.004, respectively) and lower DMFS 
(log-rank test, P = 0.039 and P = 0.016), (Figure 1D). 
The high expression level of CCL2/CCR2 axis was 
also significantly associated with distant metastasis, 
progression and death (P = 0.023, 0.036 and 0.019, 
respectively). Cox multivariate analysis including 
age, gender, WHO histological grade, T stage, N stage, 
clinical stage, CCL2 and CCR2 status was performed, 
which revealed that overexpression of CCR2 was one 
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Figure 1: (A) Representative of CCL2 expression and CCR2 expression in NPC tumor tissue and non-tumor tissue detected by IHC. 
(B) Upregulations of CCL2 and CCR2 were observed in different NPC cell lines compared with non-tumor control. NP69 was set as an 
control. (C) Result from ELISA analyses of human sera, the mean serum CCL2 concentration of 50 NPC patients was significantly higher 
than the mean serum CCL2 concentration of 50 non-NPC patients’. *P < 0.05. (D) Kaplan-Meier analysis indicates both upregulation of 
CCL2 and upregulation of CCR2 were significantly associated with poorer overall survival and distant metastasis-free survival of NPC 
patients (p = 0.011, p = 0.039, p = 0.004, p = 0.016, respectively). 
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Table 1: Clinicopathological correlation of CCL2 expression and CCR2 expression in NPC
Clinical
factor
Cases
(n = 107)
CCL2 expression
P value
CCR2 expression
P valueHigh
(n = 48)
Low
(n = 59)
High
(n = 55)
Low
(n = 52)
Sex
 male 83 (77.6%) 40 43 0.143 42 41 0.854
 female 24 (22.4%) 8 16 13 11
Ages (years)
 < 50 67 (62.6%) 25 42 0.065 37 30 0.496.
 ≥ 50 40 (37.4%) 23 17 18 22
T stage 
 T1 + T2 60 (56.1%) 26 34 0.589 29 31 0.484
 T3 + T4 47 (43.9%) 22 25 26 21
N stage
 N0 + N1 78 (72.9%) 41 37 0.005 40 38 0.953
 N2 + N3 29 (27.1%) 7 22 15 14
Clinical stage
 I + II 45 (42.1%) 25 20 0.138 21 24 0.382
 III + IVa + b 62 (57.9%) 23 39 34 28
Local-regional relapse
 No 91 (85.0%) 41 50 0.810 43 48 0.056
 Yes 16 (15.0%) 7 9 12 4
Distant metastasis
 No 85 (79.4%) 34 51 0.062 39 46 0.032
 Yes 22 (20.6%) 14 8 16 6
Progression
 No 70 (65.4%) 26 44 0.080 28 42 0.001
 Yes 37 (34.6%) 22 15 27 10
Death
 No 67 (62.6%) 24 43 0.016 28 39 0.011
 Yes 40 (37.4%) 24 16 27 13
Statistical significance (p < 0.05) is shown in bold and italic.
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of the independent prognostic factors of poorer OS 
(P = 0.012) and DMFS (P = 0.045) of NPC patients 
(Table 2). 
Overexpression of either CCL2 or CCR2 
promotes the migration and invasion of poorly 
metastatic NPC cells without influencing general 
cell growth, contact-independent cell growth, 
and anchorage-independent cell growth
To determine the oncogenic function of CCL2 and 
CCR2, they were separately overexpressed in two NPC cell 
lines (S26 and SUNE1). Ectopic expressions of CCL2 and 
CCR2 were determined by Western blotting (Figure 2A).
Functional assays including cell growth curves, foci 
formation and colony formation in soft agar were applied 
to determine the tumorigenicity of CCL2/CCR2. None 
of them showed CCL2 or CCR2 could promote NPC 
cell growth rate, tumor formation in contact-independent 
cell growth or anchorage-independent cell growth 
(Figure 2B, 2C and 2D). However, transwell of migration 
assays indicated either CCL2- or CCR2- overexpressed 
cells not only migrated more than control cells during 
the same time, but also invaded Matrigel more and 
quicker compared with their controls in invasion assays 
(Figure 3A and 3D).
Overexpression of either CCL2 or CCR2 
increases distant metastasis of NPC mice models
To evaluate the in vivo effects of CCL2 and CCR2 
on tumor metastasis, same amount of S26-CCL2, S26-
CCR2 or S26-vec cells were injected into nude mice 
(6 mice per group) intravenously through the tail vein, 
respectively. After 5 weeks, the mice were sacrificed and 
metastatic nodules at surface of lungs and livers were 
counted. The results showed that the number of metastatic 
nodules formed at the surface of the lungs of S26-CCL2 
and S26-CCR2 were significantly higher than the number 
of S26-vec (P < 0.05, P < 0.01, respectively, independent 
student’s t test. Figure 3B). 
To cross-verify the role of CCL2 or CCR2 
promoting distant metastasis in vivo, same procedures 
as described above were applied to mice models with 
SUNE1-CCL2 or SUNE1-CCR2 or SUNE1-vec cells. A 
similar but not identical outcome showed that, the number 
of metastatic nodules formed at the surface of the lungs of 
SUNE1-CCR2 was significantly higher than the number of 
SUNE1-vec (P < 0.05, independent student’s t test), while 
the amount of SUNE1-CCL2 showed no difference from 
SUNE1-vec (Figure 3E). Hematoxylin and eosin (H&E) 
staining confirmed that the nodules on the surfaces of mice 
lungs were metastatic tumors (Figure 3C and 3F).
Silence of either CCL2 or CCR2 inhibits the 
migration and invasion of highly metastatic  
NPC cells without influencing general cell 
growth, contact-independent cell growth and 
anchorage-independent cell growth
To further confirm if CCL2 or CCR2 influence 
cell mobility in migration and invasion without affecting 
tumor formation, silencing either CCL2 or CCR2 in two 
highly metastatic cell lines (S18 and 5-8F) was performed 
by RNA interference (RNAi) with two shRNAs targeting 
CCL2 (shRNA-CCL2-1 and shRNA-CCL2-2) or CCR2 
(shRNA-CCR2-1 and shRNA-CCR2-2). A scramble 
shRNA was used as a control (shc). Western blotting 
showed that significant deduction of CCL2/CCR2 in 
protein level was detected (Figure 2E). 
Functional assays of cell growth curves, foci formation 
and colony formation in soft agar revealed that NPC cell 
growth rate, the contact-independent cell growth, and the 
anchorage-independent cell growth were not significantly 
interfered in CCL2/CCR2 silencing cells, compared with 
control cells (Figure 2E, 2G and 2H). Nevertheless, in both 
cell lines, CCL2-silencing and CCR2-silencing performed 
significantly attenuated ability of migration and invasion 
than control cells (Figure 4A and 4D). 
Silence of either CCL2 or CCR2 decreases 
distant metastasis of NPC mice models
To authenticate moreover if CCL2/CCR2 silencing 
in highly metastatic cells could inhibit the in vivo 
metastasis, same amount of shRNA-transfected cells 
(S18-shRNA-CCL2-1, S18-shRNA-CCL2-2, S18-shRNA-
CCR2-1 or S18-shRNA-CCR2-2 and 58F-shRNA-
CCL2-1, 58F-shRNA-CCL2-2, 58F-shRNA-CCR2-1 
or 58F-shRNA-CCR2-2) and their controls (shc) were 
injected into nude mouse (6 mice per group) intravenously 
through the tail vein, respectively. Organs including the 
lungs and livers of the mice were harvested after 5 weeks. 
The results showed that silencing either CCL2 or CCR2 
could remarkably inhibit distant metastasis of NPC cells, 
mostly in lungs. Similar results were found in both cell 
lines (Figure 4B and 4E). H&E staining was performed 
to validate the nodules on the surfaces of mice lungs were 
metastatic tumors (Figure 4C and 4F). 
Overexpression of CCL2/CCR2 axis further 
enhances the migration and invasion of poorly 
metastatic NPC cells
Since either CCL2 or CCR2 could upgrade the 
ability of metastasis of NPC cells individually, a further 
investigation to overexpress the whole CCL2/CCR2 axis 
by adding exogenous CCL2 in CCR2-overexpression cells 
(SUNE1-CCR2+CCL2) was conducted. Transwell assays 
of migration and invasion within subgroups of SUNE1 
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(SUNE1-vec, SUNE1-CCL2, SUNE1-CCR2 and SUNE1-
CCR2+CCL2) showed that CCR2-overexpression cells 
cultured with exogenous CCL2 presented the strongest 
ability of both migration and invasion among them, 
though CCL2-overexpression or CCR2-overexpression 
also showed enhancement of migration and invasion 
compared with the vector control (Figure 5A). 
The suppression of migration and invasion of 
highly metastatic NPC cells by silencing CCR2 
fails to be rescued by exogenous CCL2 
On the other hand, to explore whether CCL2 could 
enhance the ability of migration and invasion without 
CCR2 (in CCR2-silencing cells), transwell assays without 
Matrigel and with Matrigel were repeated in the two highly 
metastatic cell lines (S18 and 5-8F). Two groups cells, 
S18 group (S18-shc, S18-shRNA-CCL2-1, S18-shRNA-
CCL2-2, S18-shRNA-CCR2-1, S18-shRNA-CCR2-
1+CCL2, S18-shRNA-CCR2-2 and S18-shRNA-CCR2-
2+CCL2) and 58F group (58F-shc, 58F-shRNA-CCL2-1, 
58F-shRNA-CCL2-2, 58F-shRNA-CCR2-1, 58F-shRNA-
CCR2-1+CCL2, 58F-shRNA-CCR2-2 and 58F-shRNA-
CCR2-2+CCL2), were investigated. The results showed 
that CCR2-silencing cells cultured with CCL2 migrated 
and invaded fewer than the controls (shc), which was 
parallel to CCL2-silencing cells or CCR2-silencing 
cells. This indicated that the suppressive competence in 
migration and invasion of highly metastatic NPC cells 
with silence of CCR2 could not be rescued by exogenous 
CCL2 (Figure 5B).
Overexpressing CCL2/CCR2 axis results in 
increased activity of ERK1/2 signaling pathway 
as measured by luciferase reporter assays
To further study the potential downstream effectors 
modulated by CCL2/CCR2 axis, luciferase experiments 
were carried out using the Cignal Finder 10 Pathway 
Reporter Arrays and Dual-Glo Luciferase Assay System. 
Among the ten different pathways, transcriptional activity 
of ERK1/2 pathway was enhanced predominantly 
when CCL2/CCR2 axis was overexpressed integrally, 
which suggested that CCL2/CCR2 axis was involved in 
transcriptional regulation or phosphorylation of ERK1/2 
pathway in NPC cells (Figure 5C).
Table 2: Cox proportional hazard regression analyses for 10-year OS and 10-year DMFS
Prognosis factor Wald Sig HR
95.0% CI for Exp (B)
Lower Upper
OS
 Age 1.601 0.206 1.629 0.765 3.471
 Gender 3.375 0.066 2.466 0.941 6.461
 WHO 0.398 0.528 0.673 0.197 2.302
 T stage 9.149 0.002 3.108 1.491 6.481
 N stage 11.433 0.001 2.452 1.458 4.123
 Clinical stage 7.956 0.005 0.306 0.135 0.697
 CCL2 0.458 0.499 1.283 0.623 2.643
 CCR2 6.350 0.012 2.570 1.233 5.355
DMFS
 Age 1.780 0.182 1.998 0.723 5.519
 Gender 3.090 0.079 3.870 0.856 17.496
 WHO 0.600 0.438 0.443 0.056 3.475
 T stage 2.976 0.084 2.382 0.889 6.387
 N stage 5.734 0.017 2.456 1.177 5.124
 Clinical stage 2.990 0.084 0.380 0.127 1.138
 CCL2 0.308 0.579 1.331 0.484 3.659
 CCR2 4.023 0.045 2.869 1.024 8.037
Abbreviations: OS, overall survival; DMFS, distant metastasis-free survival; CI = confidence interval; HR = hazard ratio.
Statistical significance (p < 0.05) is shown in bold and italic.
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Figure 2: (A) Relatively high expressions of CCL2 and CCR2 were respectively confirmed by Western blotting in CCL2/CCR2- 
overexpressed S26 and SUNE1 cells compared with vector control cells. (B) Cell growth rates between CCL2-, CCR2- and empty vector-
transfected cells were compared by XTT assay. (C) Representatives and summaries of foci formations in monolayer culture induced by 
CCL2 and CCR2 and its vector control. (D) Representatives of soft agar assays for colony formation induced by CCL2 and CCR2 and its 
vector control. (E) Decreased expressions of CCL2 and CCR2 were respectively confirmed by Western blotting in CCL2/CCR2- silenced 
S18 and 58F cells compared with scramble shRNA control cells. (F) Cell growth rates between CCL2-, CCR2- and scramble shRNA 
control cells were compared by XTT assay. (G) Representatives and summaries of foci formations in monolayer culture induced by CCL2 
and CCR2 and its scramble shRNA control cells. (H) Representatives of soft agar assays for colony formation induced by CCL2 and CCR2 
and its scramble shRNA control cells.
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Figure 3: (A–D) Overexpression of CCL2 and overexpression of CCR2 respectively promotes the migration and invasion of poorly 
metastatic NPC cells. Representative pictures and summaries showed that both CCL2 and CCR2 could promote cell migration and 
cell invasion in S26 and SUNE1 cells compared with vector control cells. *P < 0.05, **P < 0.01. (B–E) Overexpression of CCL2 and 
overexpression of CCR2 respectively increases distant metastasis in vivo. Representative pictures of lungs derived from mice injected with 
CCL2-, CCR2- and empty vector-transfected S26 cells and SUNE1 cells. Visible tumor nodules were counted and summarized. *P < 0.05. 
(C–F) H&E staining was performed on pulmonary sections derived from mice. Original magnification: 20 × objective.
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Figure 4: (A–D) Silencing CCL2 and silencing CCR2 respectively inhibits the migration and invasion of highly metastatic NPC 
cells. Representative pictures and summaries showed that silencing CCL2 and silencing CCR2 respectively could inhibit cell 
migration and cell invasion in S18 and 58F cells compared with scramble shRNA control cells. *P < 0.05, **P < 0.01, ***P < 0.001. 
(B–E) Silencing CCL2 and silencing CCR2 respectively decreases distant metastasis in vivo. Representative pictures of lungs derived 
from mice injected with shCCL2-, shCCR2- and scramble shRNA control S18 cells and 58F cells. Visible tumor nodules were counted 
and summarized. *P < 0.05, ***P < 0.001. (C–F) H & E staining was performed on pulmonary sections derived from mice. Original 
magnification: 20 × objective.
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CCL2/CCR2 axis stimulates cell mobility by 
upregulating MMP2 and MMP9 expression via 
phosphorylating ERK1/2 signaling pathway
Western blot analysis was used to further confirm 
that overexpressing CCL2/CCR2 axis could activate 
ERK1/2 pathway. The phosphorylated sites of ERK1/2 
signaling pathway including p-44/42, p-MEK, p-c-Raf, 
p-90RSK and p-MSK were detected in CCL2/CCR2-
overexpressed cells (SUNE1-CCR2/CCL2) compared with 
the control. On the contrary, there was no phosphorylation 
at the key sites of ERK1/2 in CCL2/CCR2-silenced 
cells (58F-shCCL2-1, 58F-shCCL2-2, 58F-shCCR2-1, 
58F-CCR2-1+CCL2, 58F-CCR2-2 and 58F-CCR2-
2+CCL2), and for the control, only p-MEK and p-90RSK 
could be detected in 58F-shc cells (Figure 5D).
It has been proven by numerous studies that MMPs 
expression could be modulated by ERK1/2 signaling 
pathway in various non-oncologic diseases and cancers. 
Among MMPs family, MMP2 and MMP9 have been 
confirmed playing important role in enhancement of tumor 
metastasis. By detecting MMP2 and MMP9 expression 
levels in CCL2/CCR2-overexpressed cells (SUNE1-
CCL2, SUNE1-CCR2, SUNE1-CCR2/CCL2) and CCL2/
CCR2-silenced cells (58F-shCCL2-1, 58F-shCCL2-2, 
58F-shCCR2-1, 58F-CCR2-1+CCL2, 58F-CCR2-2, 
58F-CCR2-2+CCL2), both of them were upregulated or 
downregulated accordingly compared with the control 
(Figure 5E), which was also consistent with the expression 
of phosphorylated sites of ERK1/2 pathway (Figure 5F).
DISCUSSION
It has been previously studied that, in the tumor 
microenvironment, inflammatory cells and molecules 
modulate many events of cancer progress, including 
tumor metastasis [34–39]. CCL2 and its receptor 
CCR2 are the chemokines largely participating in 
tumor microenvironment by regulating macrophage 
mobilization and infiltration [40, 41], and also by 
recruiting inflammatory monocytes from bone marrow to 
peripheral sites of inflammation [15]. Plenty of researches 
suggest that CCL2/CCR2 is related to poor outcome and 
metastatic events in several cancers [15, 18, 23, 42–44]. 
In this study, we investigated the metastatic 
enhancement of CCL2/CCR2 axis in NPC both in vitro 
and in vivo. Our main advantages are as following: First, 
the ample patient resource with 10-years follow-up from 
NPC endemic area, which made the outcome more reliable 
in respect of clinical prognosis. Second, we used two 
pair clones with highly metastatic and poorly metastatic 
potential (S18 and S26, 58F and SUNE1), which are 
derived from single parental cell line of each other (CNE2 
and SUNE1, respectively). As reported previously, tumor 
metastases usually arise from rare clones in the tumor [45], 
thus using identified clones for comparison may disclose 
the pivotal molecules in tumor metastasis distinctly [46]. 
And most of all, we gained insights into four significant 
aspects of how CCL2/CCR2 influence NPC metastasis in 
a spatial and temporal manner as follows. 
First, sufficient clinical-data in human tissues and 
sera showed CCL2/CCR2 were dramatically upregulated 
in NPC patients compared to nontumor cases, and also 
negatively correlated to 10 yr OS and DMFS in 107 
NPC cases. This suggested that CCL2/CCR2 played an 
important role in the distant metastasis of NPC.
 Second, the overexpression of either CCL2 or 
CCR2 respectively in poorly metastatic NPC cell lines 
(S26, SUNE1) could enhance cell migration and invasion 
in vitro, and promote metastasis in vivo. On the other hand, 
silencing CCL2 or CCR2 respectively in highly metastatic 
NPC cell lines (S18, 58F) could inhibit cell migration 
and invasion in vitro, and attenuate metastasis in vivo. 
Interestingly, whether upregulating or downregulating 
CCL2/CCR2, tumorigenesis was not be influenced in two 
independent cell-line pairs, arguing against the possibility 
that the observed increment or reduction in metastasis are 
the result of tumor growth rate. Based on these findings, 
we raise a perception that by different mechanisms tumor 
growth and metastasis of NPC could be modulated. CCL2/
CCR2 might probably act upon various steps of metastasis 
rather than tumorigenesis. In line with our results, previous 
work from Sawanobori et al. also indicated that CCR2 
deficiency did not affect primary tumor growth [42, 47]. 
Recent observations that CCL2 overexpression in tumor 
cells increased metastasis [42, 48] are in accordance with 
our findings. 
Third, NPC cell mobility could be tremendously 
facilitated in functional studies when the expression of 
CCL2 and CCR2 was overexpressed as an integrated axis 
by adding exogenous CCL2 in CCR2-overexpressed cells, 
and a validation in vivo is expected in our further study. 
On the other hand, the inner interaction within CCL2/
CCR2 axis was also unveiled to draw a map that, CCR2 
would probably be the onset-limiting part in the axis, 
for exogenous CCL2 failed to rescue the inhibited cell 
migration and invasion when CCR2 was insufficient. This 
finding coincides with a significant outcome of a profound 
research in colon carcinoma [42]. 
Last but not least, upregulation of MMP2 and 
MMP9 through ERK1/2 signaling pathway was identified 
as the metastasis-promoting mechanism of CCL2/CCR2 
axis in NPC. It is well-known that the MAPK pathways 
(i.e. ERK1/2, JNK, and p38) participate in numerous 
signaling cascades that play regulatory roles in cell 
growth, apoptosis, differentiation, and metastasis [49]. 
Recently, there are several researches in Hela cells, breast 
cancer, colon carcinoma and melanoma showing CCL2/
CCR2 axis is related to the activation of MAPK pathways 
in ERK1/2, p38, and JNK [42, 50–52]. It has also been 
reported that ERK1/2 could regulate expression levels 
of MMP2 and MMP9 in cancer cells, which can degrade 
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Figure 5: (A) Overexpression of CCL2/CCR2 axis further facilitates the migration and invasion of poorly metastatic NPC cells. 
Representative pictures and summaries showed that adding exogenous CCL2 to CCR2-overexpressed cells could intensively promote 
cell migration and cell invasion in SUNE1 cells compared with vector control cells and individual CCL2/CCR2-overexpressed cells. 
*P < 0.05, **P < 0.01, ***P < 0.001. (B) The suppressive motility of cell migration and invasion of highly metastatic NPC cells inhibited 
by silencing CCR2 were failed to be rescued by exogenous CCL2. Representative pictures and summaries showed that adding exogenous 
CCL2 to CCR2-silenced cells could not promote cell migration and cell invasion in 58F cells compared with scramble shRNA control cells, 
and individual shCCL2/shCCR2 cells. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Luciferase reporter assay was performed separately in cells 
of CCL2/CCR2 overexpressed integrally (left) and respectively (right). Remarkable activation of ERK1/2 signaling pathway is observed 
in CCL2/CCR2 axis integrally upregulated while no transcriptional activity is distinctive when CCL2/CCR2 respectively overexpressed. 
(D) Western blotting showed that five phosphorylated key-proteins of ERK1/2 signaling pathway were increased in CCL2/CCR2 axis 
overexpressed SUNE1 cells compared with vector control cells and individual CCL2 or CCR2-overexpressed cells (left). Total ERK1/2 
was set as an internal control. And only two of the five phosphorylated key-proteins of ERK1/2 signaling pathway were detected in 58F 
scramble shRNA control cells and all five were under detectable in 58F CCL2/CCR2-silenced cells (right). (E) MMP2 and MMP9 were 
compared between CCL2/CCR2 axis-, individual CCL2/CCR2- and vector-transfected cells in SUNE1 (left), or between shCCL2/CCR2- 
and shCCR2-cultured with exogenous CCL2, and scramble shRNA control cells (right) in 58F by Western blotting. β-Tubulin was used as 
a loading control. (F) Schematic plot of CCL2/CCR2 axis in promoting metastasis: CCL2 binds CCR2 to form activated CCL2/CCR2 axis, 
which phosphorylates ERK1/2 and consequently upregulates MMP2/MMP9, then increases cell migration and invasion and eventually 
promotes tumor metastasis.
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extracellular matrix to promote metastasis in tumor 
[53–56]. Similarly, we identified CCL2/CCR2 axis as a 
tumor promoter in NPC metastasis through upregulating 
MMP2/9 via ERK1/2 pathways. Besides, in other studies 
published recently, CCL2/CCR2 axis also has been 
found to interact with STAT, JAK, and Smad signaling 
[42, 51, 57, 58], implying it might participate in extensive 
biological activities. Interestingly, an incomprehensive 
finding of the inconsistency of metastasis mechanisms in 
CCL2/CCR2 axis activated integrally and individually was 
observed. Cignal Finder 10 Pathway Reporter Arrays of 
CCL2- or CCR2-overexpressed cells showed no obvious 
change in transcriptional activity of the ten pathways, with 
only minor increase in Wnt, cAMP/PKA and MAPK/JNK. 
Intriguingly, ERK1/2 signaling pathway was distinguished 
with high transcriptional activity when CCL2/CCR2 axis 
was overexpressed integrally by adding exogenous CCL2 
in CCR2-overexpressed cells. The immunoblotting analysis 
of ERK1/2 pathway also demonstrated its activation. 
Lately the antagonists to CCL2 and CCR2 are 
available and some of them are being used in clinical 
trials, which can be expected in the treatment of distant 
metastasis of NPC. Recently, however, one remarkable 
study published on Nature alerted that, cessation of CCL2 
inhibition would accelerate breast cancer metastasis 
in mice [59]. Though this phenomenon is not widely 
observed in other cancers yet, attention should be aroused 
when suppressing CCL2/CCR axis is applied for tumor 
treatment. Taking this distinctive occurrence and our 
findings together, we modestly suggest that, under the 
circumstance of consecutive and steady administration, 
inactivating CCL2/CCR2 axis, especially CCR2, would 
be a promising treatment of NPC.
The limits of our study are also concerned. We 
failed to establish a stable cell line to overexpress CCL2 
and CCR2 simultaneously, instead, we added exogenous 
CCL2 in the culture medium of CCR2-overexpressed cells 
to imitate the overexpression of CCL2/CCR2 axis in vitro. 
Also, we did not carry out animal models to confirm the 
promoted mobility or metastasis of cells overexpressing 
CCL2/CCR2 axis due to limited fund. On the other side, 
we did not investigate the function of silencing CCL2/
CCR2 axis integrally in vitro or in vivo. 
In conclusion, CCL2/CCR2 axis plays an important 
role in the promotion of NPC metastasis by upregulating 
MMP2 and MMP9 via activating ERK1/2 pathway, which 
may lead to the identification of new therapeutic targets 
for distant metastasis of NPC. 
MATERIALS AND METHODS
NPC samples and cell lines
A number of 50 primary NPC tumor samples and 
another 50 nontumorous samples were immediately 
collected from total 100 NPC patients who underwent 
nasopharyngeal biopsy in electric nasopharyngoscopy 
at Sun Yat-Sen University Cancer Center (SYSUCC), 
Guangzhou, China, before treatment. All samples used in 
this study were approved by the Committees for Ethical 
Review of Research at Sun Yat-Sen University. 
Four human NPC cell lines, S18 and S26 (highly 
metastatic clone and poorly metastatic clone of CNE-2), 
SUNE-1 and its highly metastatic clone 58F, were kindly 
provided by Professor Qian Chaonan (Department of 
Nasopharyngeal carcinoma, SYSUCC, Guangzhou, 
China). All these cell lines were cultured in less than 20 
passages, and maintained in DMEM (Dulbecco’s modified 
Eagle’s medium) supplemented with 10% FBS at 37°C. 
Regular morphologic observation and test for absence 
of mycoplasma contamination (MycoAlert, Lonza) were 
authenticated in all cell lines used in the present study.
Human tissues, immunohistochemical staining 
and histologic evaluation
A total number of 107 formalin-fixed and 
paraffin-embedded NPC specimens were obtained from 
pathologically diagnosed patients at SYSUCC between 
August of 1999 and March of 2000. This cohort consisted 
of 83 male and 24 female patients, giving a male: female 
ratio of 3.46:1, and the median patient age was 47 years 
(range 18–91 years). Proportions of patients with late 
T stage (T3-4) and late N stage (N2-3) were 43.9% and 
27.1%, respectively (Table 1). All patients received 
radiotherapy with doses of 60 to 80 Gy to nasopharynx 
and 50 to 80 Gy to the neck. 
In immunohistochemical (IHC) analysis of 
CCL2 and CCR2, the paraffin-embedded slices were 
deparaffinized, rehydrated, and blocked by 5% bovine 
serum albumin (BSA) at room temperature for 20 minutes, 
then incubated with rabbit polyclonal antibody against 
CCL2 (bs-1955R, Bioss) /CCR2 (bs-0562R, Bioss) at 
a dilution of 1:100 at 4°C overnight, and subsequently 
incubated with horseradish peroxidase (HRP) anti-rabbit/
mouse immunoglobulin at a concentration of 1:100 for 
30 minutes at 37°C, then detected the primary antibodies 
followed by 3, 3-diaminobenzidine substrate visualization 
and counterstaining with hematoxylin (GTVision III 
Detection System/Mo & Rb). The IHC staining index 
was calculated independently by two pathologists, adding 
the scores for the intensity of CCL2-positive staining 
or CCR2-positive staining (negative, 0; weak, 1; moderate, 
2; or strong, 3) and the percentage of CCL2-positive 
cells or CCR2-positive cells (< 25%, 1; 25%–50%, 2; > 
50%–75%, 3; > 75%, 4 scores). The final score was the 
average value from the two referees.
Lungs and livers of nude mice with distant 
metastasis were formalin-fixed and paraffin-embedded 
and sectioned at 5 mm throughout the organs and one 
section in every 20 sequential sections was selected for 
hematoxylin and eosin staining.
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Human sera and enzyme-linked immunosorbent 
assay (ELISA) 
From Nov 2009 to Dec 2009，100 serum samples 
including 50 non-tumor patients (normal control) and 
50 histologically verified NPC patients were collected 
before treatment in Department of NPC at Sun Yat-Sen 
University Cancer Center.
The concentration of serum CCL2 (sCCL2) was 
measured with commercially available human CCL2 
quantitative ELISA kit (R&D Systems, Minneapolis, 
MN, USA) according to the instructions provided 
by the manufacturer. After the reaction, a value at 
wavelength of 450 nm was measured with enzyme-linked 
spectrophotometer, and the concentration of sCCL2 was 
calculated from the standard curve. All analyses were 
made in duplicate and the mean value was used for 
statistical analysis. 
Plasmid constructs and transfection
Either full-length of CCL2 cDNA or CCR2 cDNA 
were amplified by polymerase chain reaction (PCR) 
and cloned into plenti6 expression vector (Invitrogen). 
Lipofectamine 2000 (Invitrogen) was used to stably 
transfect CCL2 and CCR2 into S26 and SUNE-1 cells, 
respectively. Blank vector-transfected cells were used as 
controls.
Establishment of CCL2 knockdown cells and 
CCR2 knockdown cells
Short hairpin RNAs (shRNA) in lentivirus against 
CCL2 (shRNA-CCL2-1, shRNA-CCL2-2) and short 
hairpin RNAs (shRNA) in lentivirus against CCR2 
(shRNA-CCR2-1, shRNA-CCR2-2) were purchased 
from GenePharma Co., Ltd (Shanghai, China) and 
stably transfected into S18 and 5-8F cells, respectively. 
Scrambled shRNA-transfected cells were used as negative 
controls.
Cell growth assay, foci formation assay, and soft 
agar assay for colony formation
For cell growth assay, cells were seeded in 96-well 
plate at a density of 1 × 103 per well and cell growth rate was 
assessed by Cell Counting Kit-8 (Dojindo). Cellular growth 
curves were plotted by using the cellular viability values.
For foci formation assay, 1 × 103 cells per well were 
seeded dispersedly in 6-well plate. After one-week culture, 
cell colonies were counted by crystal violet staining. The 
results are expressed as mean ± SD of three independent 
experiments. 
For soft agar for colony formation, 0.5 ml DMEM 
supplemented with 10% FBS containing 1 × 103 cells 
per well were mixed with 1.5 ml 0.6% soft agar-DMEM 
(10% FBS), then seeded on pre-established base agar 
[0.6% soft agar-DMEM (10% FBS)] in 6-well plate. 
Incubate assay at 37°C for three weeks then counted 
sphere-colonies by using a dissecting microscope. The 
results are expressed as mean ± SD of three independent 
experiments. 
In vitro migration and invasion assays
Migration assays were conducted with Biocoat 
without Matrigel (Corning. Life sciences) and invasion 
assays were performed with Biocoat with Matrigel 
(Corning. Life sciences) following the manufacturer’s 
instructions. The reaped Biocoats were then stained 
with crystal violet and invaded cells were counted 
under a microscope. Both experiments were repeated 
independently in three times.
In vivo distant metastasis assays
Male nude mice between 4 and 5 weeks of age 
were obtained from Guangdong Medical Laboratory 
Animal Center (Guangzhou, China). All the animal 
studies were conducted in accordance with the principles 
and procedures outlined in the guidelines of Institutional 
Animal Care and Use Committee at SYSUCC.
CCL2 overexpressing cells or CCR2 overexpressing 
cells (1 × 107 for S26-CCL2; 1 × 107 for S26-CCR2; 
1 × 107 for SUNE1-CCL2; 1 × 107 for SUNE1-CCR2), 
CCL2 silencing cells or CCR2 silencing cells (2 × 106 
for S18-shCCL2-1; 2 × 106 for S18-shCCL2-2; 2 × 106 
for S18-shCCR2-1; 2 × 106 for S18-shCCR2-2; 2 × 106 
for 58F-shCCL2-1; 2 × 106 for 58F-shCCL2-2; 2 × 106 
for 58F-shCCR2-1; 2 × 106 for 58F-shCCR2-2), or control 
cells (1 × 107 for S26-vec, 1 × 107 for SUNE1-vec, 
2 × 106 for S18-shc, 2 × 106 for 58F-shc) were 
subcutaneous injected intravenously through the tail vein 
in the mice, respectively. Distant metastases in lungs and/
or livers were checked and counted after 5 weeks when 
mice were sacrificed. Lungs and livers were excised and 
embedded in paraffin for further study.
Immunoblotting
Western blot analyses were performed with the 
standard protocol.
The primary antibodies, including rabbit anti-
human CCL2 polyclonal antibody (#2027 Cell Signaling 
Technology), rabbit anti-human CCR2 monoclonal 
antibody (#12199 Cell Signaling Technology), phospho-
Erk1-2 Pathway Kit (#9911 Cell Signaling Technology), 
mouse anti-human MMP2 polyclonal antibody (#4022 
Cell Signaling Technology), rat anti-human MMP9 
polyclonal antibody (#3852 Cell Signaling Technology), 
and β-tubulin monoclonal antibody (#5346 Cell Signaling 
Technology) were used at a dilution of 1:1,000.
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Luciferase reporter assay
Two independent assays were carried out.
SUNE1-CCL2, SUNE1-CCR2, and SUNE1-vector 
cells for the first assay and, SUNE1-CCR2 cells pretreated 
with exogenous CCL2 and SUNE1-vector cells for the 
second assay, were seeded in Cignal Finder 10-Pathway 
Reporter Array plates (QIAGEN, Dusseldorf, GER) when 
the cell density and cell viability met the transfection 
condition. Protocol of Luciferase Cignal Finder 
Reporter Array Plate Format Handbook was followed 
for developing the assays. Dual-Glo Luciferase Assay 
System (Promega, Madison, WI) was used to measured 
dual luciferase signals after reverse transfection.
Statistics
SPSS statistics 19.0 was used for data analysis. Single 
comparisons were performed by Student’s t test, Mann–
Whitney test, or χ2 test (2-tailed; P < 0.05 was considered 
significant). Clinical correlation study was analyzed by 
Pearson χ2 test. Kaplan-Meier plots and log-rank tests were 
used for survival analysis. Cox’s regression model was 
used for multivariate analysis. The median of the IHC score 
value was used as the cut-off point to divide the patients into 
high- and low-CCL2/CCR2 expression groups. Differences 
were considered significant when P < 0.05.
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